Cellectar Biosciences Inc

Discover how Cellectar Biosciences’ Q3 2025 results reflect a strategic focus on oncology R&D, a tighter balance sheet, and a potential path to future revenue.

Cellectar Biosciences Inc. is set to release its Q2 2025 earnings on August 14, 2025, with analysts expecting a loss of $3.719 per share.

Cellectar Biosciences Inc.’s stock surged 147% after the FDA granted Breakthrough Therapy Designation to its cancer treatment drug candidate, Iopofosine I 131, for Waldenstrom Macroglobulinemia.

Cellectar Biosciences Inc. continues to navigate challenges in the biotech sector, but remains committed to advancing innovative cancer treatments and therapies through its research and development pipeline.

Cellectar Biosciences Inc.’s stock price has significantly declined, raising concerns about the company’s financial health and future prospects, despite its promising focus on cancer treatment and diagnosis.

Cellectar Biosciences is exploring strategic alternatives, including mergers and acquisitions, to enhance shareholder value and revitalize its prospects in the biotechnology sector.